Genomics and the future direction of health research

Dr Andrew Fry Director, Wales Gene Park Clinical Senior Lecturer in Medical Genetics Institute of Medical Genetics, Cardiff <u>fryae@cardiff.ac.uk</u>



Ymchwil lechyd a Gofal <mark>Cymru</mark> Health and Care Research <mark>Wales</mark>

What are the aims of genomic health research?

- Identify the genetic causes of disease
- Predict a person's risk of developing disease guide prevention strategies
- Diagnose diseases more quickly
- Predict responses to different treatments precisely tailor treatment
- Classify cancers to guide treatment choices

Bigger data – international genomic projects


- deCODE (Iceland) 160,000+
- UK Biobank 500,000
- All of Us Research Program (US, 2018-2023) 1 million
- European '1+ Million Genomes' Initiative (2020-2022)
- Chinese Millionome Database (CMDB) ? Million
- National genome projects Australia, Canada, Dubai, Estonia, France, Hong Kong, Japan, Netherlands, Qatar, Saudi Arabia, Singapore, South Korea, Sweden, and Turkey

Major UK genomic projects

- 100,000 Genomes Project (2013-18) 120,239 genomes from 86,618 participants (rare disease and cancer)
- UK Government ambition 5 million genomes in the UK by 2023/24 (includes 500,000 from UK Biobank and 500,000 from NHS Genomic Medicine Service (GMS) in England.
- Our Future Health (2022+) 5 million recruits. Common chronic disease. Polygenic risk scores.

Monogenic e.g. cystic fibrosis

Polygenic e.g. coronary artery disease



V = genetic risk variant


Genomic testing techniques for rare and inherited disease


Current:

- Exome sequencing (all genes but only protein making bits) ~£700
- Whole genome sequencing (all genes and bits in between) = ~£2,000 (50x more data, ~5% more diagnoses!)

R&D stage:


- Transcriptome (RNA sequencing analysis)
- Long-read sequencing (detailed structural information)





Polygenic risk scores (PRS) for common disease

- PRS = weighted count of multiple genetic markers
- Risk variants identified by large epidemiological studies (genome-wide association studies)
- PRS available for many conditions such as coronary artery disease, type 2 diabetes, and cancers
- Cheaper than sequencing for monogenic disease use "SNP-chips"
- PRS struggle to capture full variance of traits limits predictive power



Questions?

Dr Andrew Fry Director, Wales Gene Park Clinical Senior Lecturer in Medical Genetics Institute of Medical Genetics, Cardiff <u>fryae@cardiff.ac.uk</u>

